138 related articles for article (PubMed ID: 35246084)
1. Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection in high-risk keratoplasty: a 5-year follow-up study.
Qi X; Wang L; Zhang X; Liu M; Gao H
BMC Ophthalmol; 2022 Mar; 22(1):101. PubMed ID: 35246084
[TBL] [Abstract][Full Text] [Related]
2. Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: one-year results of a randomized clinical trial.
Faramarzi A; Abbasi H; Feizi S; Hadi Y; Azari AA; Karimian F; Jafarinasab MR; Kheiri B
Eye (Lond); 2021 Oct; 35(10):2879-2888. PubMed ID: 33414533
[TBL] [Abstract][Full Text] [Related]
3. Keratoplasty postoperative treatment update.
Shimmura-Tomita M; Shimmura S; Satake Y; Shimazaki-Den S; Omoto M; Tsubota K; Shimazaki J
Cornea; 2013 Nov; 32 Suppl 1():S60-4. PubMed ID: 24104936
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Immunosuppressants in High Rejection Risk Keratoplasty: A Meta-Analysis of Comparative Studies.
Yu K; Lian XF; Jiang XY; Zhou SY
Cornea; 2021 Jun; 40(6):800-807. PubMed ID: 33941717
[TBL] [Abstract][Full Text] [Related]
5. [The effectiveness and safety of topical 0.1% tacrolimus after high-risk penetrating keratoplasty].
Li X; Zhang YN; Yin MY; Pan ZQ
Zhonghua Yan Ke Za Zhi; 2019 Jun; 55(6):419-427. PubMed ID: 31189271
[No Abstract] [Full Text] [Related]
6. [Systematic review of penetrating keratoplasty rejection treated by immunosuppressants].
Sun YJ; Li AP; Pan ZQ; Luo F; Zou LH
Zhonghua Yan Ke Za Zhi; 2010 Dec; 46(12):1122-7. PubMed ID: 21211228
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine.
Yamazoe K; Yamazoe K; Yamaguchi T; Omoto M; Shimazaki J
Cornea; 2014 Nov; 33(11):1157-63. PubMed ID: 25255133
[TBL] [Abstract][Full Text] [Related]
8. Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study.
Zhai LY; Zhang XR; Liu H; Ma Y; Xu HC
Eye (Lond); 2020 Sep; 34(9):1600-1607. PubMed ID: 31784702
[TBL] [Abstract][Full Text] [Related]
9. Topical corticosteroids with topical cyclosporine A versus topical corticosteroids alone for immunological corneal graft rejection.
Marques RE; Leal I; Guerra PS; Barão RC; Quintas AM; Rodrigues W
Eur J Ophthalmol; 2022 May; 32(3):1469-1481. PubMed ID: 34231398
[TBL] [Abstract][Full Text] [Related]
10. [The observation of tacrolimus eye drops preventing the early immunological rejection after penetrating keratoplasty for fungal keratitis].
Xiang DM; Wang YX; Jia YN; Li SX; Zhai HL; Shi WY; Gao H
Zhonghua Yan Ke Za Zhi; 2017 Apr; 53(4):305-310. PubMed ID: 28412805
[No Abstract] [Full Text] [Related]
11. Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial.
Hashemian MN; Latifi G; Ghaffari R; Ghassemi H; Zarei-Ghanavati M; Mohammadi SF; Yasseri M; Fallah Tafti MR; Tafti ZF
Cornea; 2018 Mar; 37(3):307-312. PubMed ID: 29215395
[TBL] [Abstract][Full Text] [Related]
12. Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial.
Shimazaki J; Tomida D; Yagi-Yaguchi Y; Satake Y; Yamaguchi T
BMC Ophthalmol; 2024 Jun; 24(1):251. PubMed ID: 38867175
[TBL] [Abstract][Full Text] [Related]
13. Topical cyclosporine in pediatric keratoplasty.
Cosar CB; Laibson PR; Cohen EJ; Rapuano CJ
Eye Contact Lens; 2003 Apr; 29(2):103-7. PubMed ID: 12695714
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial.
Sinha R; Jhanji V; Verma K; Sharma N; Biswas NR; Vajpayee RB
Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1167-72. PubMed ID: 20414783
[TBL] [Abstract][Full Text] [Related]
15. Topical tacrolimus in high-risk corneal transplants.
Bernardes L; Gil J; Costa E; Tavares C; Rosa A; Quadrado MJ; Murta J
Eur J Ophthalmol; 2024 Jan; 34(1):140-145. PubMed ID: 37128645
[TBL] [Abstract][Full Text] [Related]
16. [Cyclosporin A combined with dexamethasone in preventing and treating immune rejection after penetrating keratoplasty].
Xi XH; Qin B; Jiang DY
Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):627-30. PubMed ID: 15804077
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment.
Zhang T; Li Z; Liu T; Li S; Gao H; Wei C; Shi W
PLoS One; 2018; 13(5):e0196571. PubMed ID: 29734357
[TBL] [Abstract][Full Text] [Related]
18. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.
McDiarmid SV; Busuttil RW; Ascher NL; Burdick J; D'Alessandro AM; Esquivel C; Kalayoglu M; Klein AS; Marsh JW; Miller CM
Transplantation; 1995 Feb; 59(4):530-6. PubMed ID: 7533345
[TBL] [Abstract][Full Text] [Related]
19. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.
Dhaliwal JS; Mason BF; Kaufman SC
Cornea; 2008 May; 27(4):488-93. PubMed ID: 18434855
[TBL] [Abstract][Full Text] [Related]
20. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.
Reinhard T; Reis A; Böhringer D; Malinowski M; Voiculescu A; Heering P; Godehardt E; Sunmacher R
Graefes Arch Clin Exp Ophthalmol; 2001 Jun; 239(5):367-72. PubMed ID: 11482341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
